Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Saratoga Health & Biotechnology C SHPCX
- NAV / 1-Day Return 13.36 / +1.91 %
- Total Assets 11.7 Mil
-
Adj. Expense Ratio
- Expense Ratio 3.350%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 250
- Status Open
- TTM Yield —
- Turnover 58%
USD | NAV as of May 31, 2024 | 1-Day Return as of May 31, 2024, 10:18 PM GMT+0
Morningstar’s Analysis SHPCX
Will SHPCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 42.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Regeneron Pharmaceuticals Inc | 5.22 | 644,868 | Healthcare |
Cencora Inc | 5.05 | 623,269 | Healthcare |
Amgen Inc | 4.59 | 566,365 | Healthcare |
McKesson Corp | 4.56 | 563,692 | Healthcare |
Tenet Healthcare Corp | 4.10 | 506,946 | Healthcare |
The Cigna Group | 4.03 | 497,933 | Healthcare |
Elevance Health Inc | 3.81 | 470,834 | Healthcare |
Exelixis Inc | 3.72 | 459,603 | Healthcare |
Cardinal Health Inc | 3.69 | 455,209 | Healthcare |
Intuitive Surgical Inc | 3.62 | 446,981 | Healthcare |